Global Intravitreal Injection of Anti-VEGF Drugs Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Intravitreal Injection of Anti-VEGF Drugs involves delivering medication directly into the vitreous humor of the eye to inhibit the action of vascular endothelial growth factor (VEGF). VEGF is a protein that promotes the growth of new blood vessels, which, in certain eye diseases, can lead to vision impairment and blindness.
Intravitreal injection of anti-VEGF drugs is a critical treatment modality for various retinal diseases that threaten vision. By inhibiting VEGF, these drugs help manage conditions like wet AMD, DME, and RVO, ultimately preserving and improving vision in affected patients.
The global Intravitreal Injection of Anti-VEGF Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Intravitreal Injection of Anti-VEGF Drugs Industry Forecast” looks at past sales and reviews total world Intravitreal Injection of Anti-VEGF Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Intravitreal Injection of Anti-VEGF Drugs sales for 2024 through 2030. With Intravitreal Injection of Anti-VEGF Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravitreal Injection of Anti-VEGF Drugs industry.
This Insight Report provides a comprehensive analysis of the global Intravitreal Injection of Anti-VEGF Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Intravitreal Injection of Anti-VEGF Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Intravitreal Injection of Anti-VEGF Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravitreal Injection of Anti-VEGF Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravitreal Injection of Anti-VEGF Drugs.
United States market for Intravitreal Injection of Anti-VEGF Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Intravitreal Injection of Anti-VEGF Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Intravitreal Injection of Anti-VEGF Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Intravitreal Injection of Anti-VEGF Drugs players cover Novartis, Roche, Regeneron, Bayer, Samsung Bioepis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Intravitreal Injection of Anti-VEGF Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Intravitreal Injection of Anti-VEGF Drugs market?
What factors are driving Intravitreal Injection of Anti-VEGF Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Intravitreal Injection of Anti-VEGF Drugs market opportunities vary by end market size?
How does Intravitreal Injection of Anti-VEGF Drugs break out by Type, by Application?
Intravitreal Injection of Anti-VEGF Drugs involves delivering medication directly into the vitreous humor of the eye to inhibit the action of vascular endothelial growth factor (VEGF). VEGF is a protein that promotes the growth of new blood vessels, which, in certain eye diseases, can lead to vision impairment and blindness.
Intravitreal injection of anti-VEGF drugs is a critical treatment modality for various retinal diseases that threaten vision. By inhibiting VEGF, these drugs help manage conditions like wet AMD, DME, and RVO, ultimately preserving and improving vision in affected patients.
The global Intravitreal Injection of Anti-VEGF Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Intravitreal Injection of Anti-VEGF Drugs Industry Forecast” looks at past sales and reviews total world Intravitreal Injection of Anti-VEGF Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Intravitreal Injection of Anti-VEGF Drugs sales for 2024 through 2030. With Intravitreal Injection of Anti-VEGF Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravitreal Injection of Anti-VEGF Drugs industry.
This Insight Report provides a comprehensive analysis of the global Intravitreal Injection of Anti-VEGF Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Intravitreal Injection of Anti-VEGF Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Intravitreal Injection of Anti-VEGF Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravitreal Injection of Anti-VEGF Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravitreal Injection of Anti-VEGF Drugs.
United States market for Intravitreal Injection of Anti-VEGF Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Intravitreal Injection of Anti-VEGF Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Intravitreal Injection of Anti-VEGF Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Intravitreal Injection of Anti-VEGF Drugs players cover Novartis, Roche, Regeneron, Bayer, Samsung Bioepis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Intravitreal Injection of Anti-VEGF Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monoclonal Antibodies
- Fusion Proteins
- Wet Age-Related Macular Degeneration
- Diabetic Macular Edema
- Macular Edema Secondary to Retinal Vein Occlusion
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Roche
- Regeneron
- Bayer
- Samsung Bioepis
- Biogen
- Outlook Therapeutics
- Kanghong Pharmaceutical
- Qilu Pharmaceutical
What is the 10-year outlook for the global Intravitreal Injection of Anti-VEGF Drugs market?
What factors are driving Intravitreal Injection of Anti-VEGF Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Intravitreal Injection of Anti-VEGF Drugs market opportunities vary by end market size?
How does Intravitreal Injection of Anti-VEGF Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Intravitreal Injection of Anti-VEGF Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Intravitreal Injection of Anti-VEGF Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Intravitreal Injection of Anti-VEGF Drugs by Country/Region, 2019, 2023 & 2030
2.2 Intravitreal Injection of Anti-VEGF Drugs Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Fusion Proteins
2.3 Intravitreal Injection of Anti-VEGF Drugs Sales by Type
2.3.1 Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Intravitreal Injection of Anti-VEGF Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Type (2019-2024)
2.4 Intravitreal Injection of Anti-VEGF Drugs Segment by Application
2.4.1 Wet Age-Related Macular Degeneration
2.4.2 Diabetic Macular Edema
2.4.3 Macular Edema Secondary to Retinal Vein Occlusion
2.4.4 Others
2.5 Intravitreal Injection of Anti-VEGF Drugs Sales by Application
2.5.1 Global Intravitreal Injection of Anti-VEGF Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Intravitreal Injection of Anti-VEGF Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Intravitreal Injection of Anti-VEGF Drugs Breakdown Data by Company
3.1.1 Global Intravitreal Injection of Anti-VEGF Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Company (2019-2024)
3.2 Global Intravitreal Injection of Anti-VEGF Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Company (2019-2024)
3.2.2 Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Company
3.4 Key Manufacturers Intravitreal Injection of Anti-VEGF Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Intravitreal Injection of Anti-VEGF Drugs Product Location Distribution
3.4.2 Players Intravitreal Injection of Anti-VEGF Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR INTRAVITREAL INJECTION OF ANTI-VEGF DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Intravitreal Injection of Anti-VEGF Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Intravitreal Injection of Anti-VEGF Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Intravitreal Injection of Anti-VEGF Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Intravitreal Injection of Anti-VEGF Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Intravitreal Injection of Anti-VEGF Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Intravitreal Injection of Anti-VEGF Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Intravitreal Injection of Anti-VEGF Drugs Sales Growth
4.4 APAC Intravitreal Injection of Anti-VEGF Drugs Sales Growth
4.5 Europe Intravitreal Injection of Anti-VEGF Drugs Sales Growth
4.6 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Growth
5 AMERICAS
5.1 Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Country
5.1.1 Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024)
5.1.2 Americas Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024)
5.2 Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024)
5.3 Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Region
6.1.1 APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Region (2019-2024)
6.1.2 APAC Intravitreal Injection of Anti-VEGF Drugs Revenue by Region (2019-2024)
6.2 APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024)
6.3 APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Intravitreal Injection of Anti-VEGF Drugs by Country
7.1.1 Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024)
7.1.2 Europe Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024)
7.2 Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024)
7.3 Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs by Country
8.1.1 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Intravitreal Injection of Anti-VEGF Drugs
10.3 Manufacturing Process Analysis of Intravitreal Injection of Anti-VEGF Drugs
10.4 Industry Chain Structure of Intravitreal Injection of Anti-VEGF Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Intravitreal Injection of Anti-VEGF Drugs Distributors
11.3 Intravitreal Injection of Anti-VEGF Drugs Customer
12 WORLD FORECAST REVIEW FOR INTRAVITREAL INJECTION OF ANTI-VEGF DRUGS BY GEOGRAPHIC REGION
12.1 Global Intravitreal Injection of Anti-VEGF Drugs Market Size Forecast by Region
12.1.1 Global Intravitreal Injection of Anti-VEGF Drugs Forecast by Region (2025-2030)
12.1.2 Global Intravitreal Injection of Anti-VEGF Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Intravitreal Injection of Anti-VEGF Drugs Forecast by Type (2025-2030)
12.7 Global Intravitreal Injection of Anti-VEGF Drugs Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.1.3 Novartis Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.2.3 Roche Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Regeneron
13.3.1 Regeneron Company Information
13.3.2 Regeneron Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.3.3 Regeneron Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Regeneron Main Business Overview
13.3.5 Regeneron Latest Developments
13.4 Bayer
13.4.1 Bayer Company Information
13.4.2 Bayer Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.4.3 Bayer Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Bayer Main Business Overview
13.4.5 Bayer Latest Developments
13.5 Samsung Bioepis
13.5.1 Samsung Bioepis Company Information
13.5.2 Samsung Bioepis Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.5.3 Samsung Bioepis Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Samsung Bioepis Main Business Overview
13.5.5 Samsung Bioepis Latest Developments
13.6 Biogen
13.6.1 Biogen Company Information
13.6.2 Biogen Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.6.3 Biogen Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Biogen Main Business Overview
13.6.5 Biogen Latest Developments
13.7 Outlook Therapeutics
13.7.1 Outlook Therapeutics Company Information
13.7.2 Outlook Therapeutics Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.7.3 Outlook Therapeutics Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Outlook Therapeutics Main Business Overview
13.7.5 Outlook Therapeutics Latest Developments
13.8 Kanghong Pharmaceutical
13.8.1 Kanghong Pharmaceutical Company Information
13.8.2 Kanghong Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.8.3 Kanghong Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Kanghong Pharmaceutical Main Business Overview
13.8.5 Kanghong Pharmaceutical Latest Developments
13.9 Qilu Pharmaceutical
13.9.1 Qilu Pharmaceutical Company Information
13.9.2 Qilu Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.9.3 Qilu Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Qilu Pharmaceutical Main Business Overview
13.9.5 Qilu Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Intravitreal Injection of Anti-VEGF Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Intravitreal Injection of Anti-VEGF Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Intravitreal Injection of Anti-VEGF Drugs by Country/Region, 2019, 2023 & 2030
2.2 Intravitreal Injection of Anti-VEGF Drugs Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Fusion Proteins
2.3 Intravitreal Injection of Anti-VEGF Drugs Sales by Type
2.3.1 Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Intravitreal Injection of Anti-VEGF Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Type (2019-2024)
2.4 Intravitreal Injection of Anti-VEGF Drugs Segment by Application
2.4.1 Wet Age-Related Macular Degeneration
2.4.2 Diabetic Macular Edema
2.4.3 Macular Edema Secondary to Retinal Vein Occlusion
2.4.4 Others
2.5 Intravitreal Injection of Anti-VEGF Drugs Sales by Application
2.5.1 Global Intravitreal Injection of Anti-VEGF Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Intravitreal Injection of Anti-VEGF Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Intravitreal Injection of Anti-VEGF Drugs Breakdown Data by Company
3.1.1 Global Intravitreal Injection of Anti-VEGF Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Company (2019-2024)
3.2 Global Intravitreal Injection of Anti-VEGF Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Company (2019-2024)
3.2.2 Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Company
3.4 Key Manufacturers Intravitreal Injection of Anti-VEGF Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Intravitreal Injection of Anti-VEGF Drugs Product Location Distribution
3.4.2 Players Intravitreal Injection of Anti-VEGF Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR INTRAVITREAL INJECTION OF ANTI-VEGF DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Intravitreal Injection of Anti-VEGF Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Intravitreal Injection of Anti-VEGF Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Intravitreal Injection of Anti-VEGF Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Intravitreal Injection of Anti-VEGF Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Intravitreal Injection of Anti-VEGF Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Intravitreal Injection of Anti-VEGF Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Intravitreal Injection of Anti-VEGF Drugs Sales Growth
4.4 APAC Intravitreal Injection of Anti-VEGF Drugs Sales Growth
4.5 Europe Intravitreal Injection of Anti-VEGF Drugs Sales Growth
4.6 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Growth
5 AMERICAS
5.1 Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Country
5.1.1 Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024)
5.1.2 Americas Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024)
5.2 Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024)
5.3 Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Region
6.1.1 APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Region (2019-2024)
6.1.2 APAC Intravitreal Injection of Anti-VEGF Drugs Revenue by Region (2019-2024)
6.2 APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024)
6.3 APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Intravitreal Injection of Anti-VEGF Drugs by Country
7.1.1 Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024)
7.1.2 Europe Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024)
7.2 Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024)
7.3 Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs by Country
8.1.1 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Intravitreal Injection of Anti-VEGF Drugs
10.3 Manufacturing Process Analysis of Intravitreal Injection of Anti-VEGF Drugs
10.4 Industry Chain Structure of Intravitreal Injection of Anti-VEGF Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Intravitreal Injection of Anti-VEGF Drugs Distributors
11.3 Intravitreal Injection of Anti-VEGF Drugs Customer
12 WORLD FORECAST REVIEW FOR INTRAVITREAL INJECTION OF ANTI-VEGF DRUGS BY GEOGRAPHIC REGION
12.1 Global Intravitreal Injection of Anti-VEGF Drugs Market Size Forecast by Region
12.1.1 Global Intravitreal Injection of Anti-VEGF Drugs Forecast by Region (2025-2030)
12.1.2 Global Intravitreal Injection of Anti-VEGF Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Intravitreal Injection of Anti-VEGF Drugs Forecast by Type (2025-2030)
12.7 Global Intravitreal Injection of Anti-VEGF Drugs Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.1.3 Novartis Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.2.3 Roche Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Regeneron
13.3.1 Regeneron Company Information
13.3.2 Regeneron Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.3.3 Regeneron Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Regeneron Main Business Overview
13.3.5 Regeneron Latest Developments
13.4 Bayer
13.4.1 Bayer Company Information
13.4.2 Bayer Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.4.3 Bayer Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Bayer Main Business Overview
13.4.5 Bayer Latest Developments
13.5 Samsung Bioepis
13.5.1 Samsung Bioepis Company Information
13.5.2 Samsung Bioepis Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.5.3 Samsung Bioepis Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Samsung Bioepis Main Business Overview
13.5.5 Samsung Bioepis Latest Developments
13.6 Biogen
13.6.1 Biogen Company Information
13.6.2 Biogen Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.6.3 Biogen Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Biogen Main Business Overview
13.6.5 Biogen Latest Developments
13.7 Outlook Therapeutics
13.7.1 Outlook Therapeutics Company Information
13.7.2 Outlook Therapeutics Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.7.3 Outlook Therapeutics Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Outlook Therapeutics Main Business Overview
13.7.5 Outlook Therapeutics Latest Developments
13.8 Kanghong Pharmaceutical
13.8.1 Kanghong Pharmaceutical Company Information
13.8.2 Kanghong Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.8.3 Kanghong Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Kanghong Pharmaceutical Main Business Overview
13.8.5 Kanghong Pharmaceutical Latest Developments
13.9 Qilu Pharmaceutical
13.9.1 Qilu Pharmaceutical Company Information
13.9.2 Qilu Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
13.9.3 Qilu Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Qilu Pharmaceutical Main Business Overview
13.9.5 Qilu Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Intravitreal Injection of Anti-VEGF Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Intravitreal Injection of Anti-VEGF Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players of Fusion Proteins
Table 5. Global Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 6. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Table 7. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Type (2019-2024) & ($ million)
Table 8. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Type (2019-2024)
Table 9. Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global Intravitreal Injection of Anti-VEGF Drugs Sale by Application (2019-2024) & (K Units)
Table 11. Global Intravitreal Injection of Anti-VEGF Drugs Sale Market Share by Application (2019-2024)
Table 12. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Application (2019-2024) & ($ million)
Table 13. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Application (2019-2024)
Table 14. Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global Intravitreal Injection of Anti-VEGF Drugs Sales by Company (2019-2024) & (K Units)
Table 16. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Company (2019-2024)
Table 17. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Company (2019-2024)
Table 19. Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers Intravitreal Injection of Anti-VEGF Drugs Producing Area Distribution and Sales Area
Table 21. Players Intravitreal Injection of Anti-VEGF Drugs Products Offered
Table 22. Intravitreal Injection of Anti-VEGF Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Intravitreal Injection of Anti-VEGF Drugs Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share Geographic Region (2019-2024)
Table 27. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Intravitreal Injection of Anti-VEGF Drugs Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country/Region (2019-2024)
Table 31. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024) & (K Units)
Table 34. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country (2019-2024)
Table 35. Americas Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 37. Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024) & (K Units)
Table 38. APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Region (2019-2024) & (K Units)
Table 39. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Region (2019-2024)
Table 40. APAC Intravitreal Injection of Anti-VEGF Drugs Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 42. APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024) & (K Units)
Table 43. Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024) & (K Units)
Table 44. Europe Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 46. Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024) & (K Units)
Table 47. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024) & (K Units)
Table 48. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 50. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Intravitreal Injection of Anti-VEGF Drugs
Table 52. Key Market Challenges & Risks of Intravitreal Injection of Anti-VEGF Drugs
Table 53. Key Industry Trends of Intravitreal Injection of Anti-VEGF Drugs
Table 54. Intravitreal Injection of Anti-VEGF Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Intravitreal Injection of Anti-VEGF Drugs Distributors List
Table 57. Intravitreal Injection of Anti-VEGF Drugs Customer List
Table 58. Global Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 59. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 60. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 61. Americas Intravitreal Injection of Anti-VEGF Drugs Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 62. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 63. APAC Intravitreal Injection of Anti-VEGF Drugs Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 64. Europe Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 65. Europe Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. Global Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 69. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Type (2025-2030) & ($ millions)
Table 70. Global Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Application (2025-2030) & (K Units)
Table 71. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Application (2025-2030) & ($ millions)
Table 72. Novartis Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Novartis Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 74. Novartis Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Novartis Main Business
Table 76. Novartis Latest Developments
Table 77. Roche Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Roche Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 79. Roche Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Roche Main Business
Table 81. Roche Latest Developments
Table 82. Regeneron Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Regeneron Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 84. Regeneron Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Regeneron Main Business
Table 86. Regeneron Latest Developments
Table 87. Bayer Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Bayer Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 89. Bayer Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Bayer Main Business
Table 91. Bayer Latest Developments
Table 92. Samsung Bioepis Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Samsung Bioepis Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 94. Samsung Bioepis Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Samsung Bioepis Main Business
Table 96. Samsung Bioepis Latest Developments
Table 97. Biogen Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Biogen Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 99. Biogen Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Biogen Main Business
Table 101. Biogen Latest Developments
Table 102. Outlook Therapeutics Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Outlook Therapeutics Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 104. Outlook Therapeutics Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Outlook Therapeutics Main Business
Table 106. Outlook Therapeutics Latest Developments
Table 107. Kanghong Pharmaceutical Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Kanghong Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 109. Kanghong Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Kanghong Pharmaceutical Main Business
Table 111. Kanghong Pharmaceutical Latest Developments
Table 112. Qilu Pharmaceutical Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Qilu Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 114. Qilu Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Qilu Pharmaceutical Main Business
Table 116. Qilu Pharmaceutical Latest Developments
Table 1. Intravitreal Injection of Anti-VEGF Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Intravitreal Injection of Anti-VEGF Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players of Fusion Proteins
Table 5. Global Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 6. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Table 7. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Type (2019-2024) & ($ million)
Table 8. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Type (2019-2024)
Table 9. Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global Intravitreal Injection of Anti-VEGF Drugs Sale by Application (2019-2024) & (K Units)
Table 11. Global Intravitreal Injection of Anti-VEGF Drugs Sale Market Share by Application (2019-2024)
Table 12. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Application (2019-2024) & ($ million)
Table 13. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Application (2019-2024)
Table 14. Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global Intravitreal Injection of Anti-VEGF Drugs Sales by Company (2019-2024) & (K Units)
Table 16. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Company (2019-2024)
Table 17. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Company (2019-2024)
Table 19. Global Intravitreal Injection of Anti-VEGF Drugs Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers Intravitreal Injection of Anti-VEGF Drugs Producing Area Distribution and Sales Area
Table 21. Players Intravitreal Injection of Anti-VEGF Drugs Products Offered
Table 22. Intravitreal Injection of Anti-VEGF Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Intravitreal Injection of Anti-VEGF Drugs Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share Geographic Region (2019-2024)
Table 27. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Intravitreal Injection of Anti-VEGF Drugs Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country/Region (2019-2024)
Table 31. Global Intravitreal Injection of Anti-VEGF Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024) & (K Units)
Table 34. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country (2019-2024)
Table 35. Americas Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 37. Americas Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024) & (K Units)
Table 38. APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Region (2019-2024) & (K Units)
Table 39. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Region (2019-2024)
Table 40. APAC Intravitreal Injection of Anti-VEGF Drugs Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 42. APAC Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024) & (K Units)
Table 43. Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024) & (K Units)
Table 44. Europe Intravitreal Injection of Anti-VEGF Drugs Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 46. Europe Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024) & (K Units)
Table 47. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Country (2019-2024) & (K Units)
Table 48. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Type (2019-2024) & (K Units)
Table 50. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales by Application (2019-2024) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Intravitreal Injection of Anti-VEGF Drugs
Table 52. Key Market Challenges & Risks of Intravitreal Injection of Anti-VEGF Drugs
Table 53. Key Industry Trends of Intravitreal Injection of Anti-VEGF Drugs
Table 54. Intravitreal Injection of Anti-VEGF Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Intravitreal Injection of Anti-VEGF Drugs Distributors List
Table 57. Intravitreal Injection of Anti-VEGF Drugs Customer List
Table 58. Global Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 59. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 60. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 61. Americas Intravitreal Injection of Anti-VEGF Drugs Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 62. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 63. APAC Intravitreal Injection of Anti-VEGF Drugs Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 64. Europe Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 65. Europe Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. Global Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 69. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Type (2025-2030) & ($ millions)
Table 70. Global Intravitreal Injection of Anti-VEGF Drugs Sales Forecast by Application (2025-2030) & (K Units)
Table 71. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Forecast by Application (2025-2030) & ($ millions)
Table 72. Novartis Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Novartis Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 74. Novartis Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Novartis Main Business
Table 76. Novartis Latest Developments
Table 77. Roche Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Roche Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 79. Roche Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Roche Main Business
Table 81. Roche Latest Developments
Table 82. Regeneron Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Regeneron Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 84. Regeneron Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Regeneron Main Business
Table 86. Regeneron Latest Developments
Table 87. Bayer Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Bayer Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 89. Bayer Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Bayer Main Business
Table 91. Bayer Latest Developments
Table 92. Samsung Bioepis Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Samsung Bioepis Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 94. Samsung Bioepis Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Samsung Bioepis Main Business
Table 96. Samsung Bioepis Latest Developments
Table 97. Biogen Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Biogen Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 99. Biogen Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Biogen Main Business
Table 101. Biogen Latest Developments
Table 102. Outlook Therapeutics Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Outlook Therapeutics Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 104. Outlook Therapeutics Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Outlook Therapeutics Main Business
Table 106. Outlook Therapeutics Latest Developments
Table 107. Kanghong Pharmaceutical Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Kanghong Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 109. Kanghong Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Kanghong Pharmaceutical Main Business
Table 111. Kanghong Pharmaceutical Latest Developments
Table 112. Qilu Pharmaceutical Basic Information, Intravitreal Injection of Anti-VEGF Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Qilu Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Product Portfolios and Specifications
Table 114. Qilu Pharmaceutical Intravitreal Injection of Anti-VEGF Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Qilu Pharmaceutical Main Business
Table 116. Qilu Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Intravitreal Injection of Anti-VEGF Drugs
Figure 2. Intravitreal Injection of Anti-VEGF Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Intravitreal Injection of Anti-VEGF Drugs Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Intravitreal Injection of Anti-VEGF Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country/Region (2023)
Figure 10. Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Monoclonal Antibodies
Figure 12. Product Picture of Fusion Proteins
Figure 13. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type in 2023
Figure 14. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Type (2019-2024)
Figure 15. Intravitreal Injection of Anti-VEGF Drugs Consumed in Wet Age-Related Macular Degeneration
Figure 16. Global Intravitreal Injection of Anti-VEGF Drugs Market: Wet Age-Related Macular Degeneration (2019-2024) & (K Units)
Figure 17. Intravitreal Injection of Anti-VEGF Drugs Consumed in Diabetic Macular Edema
Figure 18. Global Intravitreal Injection of Anti-VEGF Drugs Market: Diabetic Macular Edema (2019-2024) & (K Units)
Figure 19. Intravitreal Injection of Anti-VEGF Drugs Consumed in Macular Edema Secondary to Retinal Vein Occlusion
Figure 20. Global Intravitreal Injection of Anti-VEGF Drugs Market: Macular Edema Secondary to Retinal Vein Occlusion (2019-2024) & (K Units)
Figure 21. Intravitreal Injection of Anti-VEGF Drugs Consumed in Others
Figure 22. Global Intravitreal Injection of Anti-VEGF Drugs Market: Others (2019-2024) & (K Units)
Figure 23. Global Intravitreal Injection of Anti-VEGF Drugs Sale Market Share by Application (2023)
Figure 24. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Application in 2023
Figure 25. Intravitreal Injection of Anti-VEGF Drugs Sales by Company in 2023 (K Units)
Figure 26. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Company in 2023
Figure 27. Intravitreal Injection of Anti-VEGF Drugs Revenue by Company in 2023 ($ millions)
Figure 28. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Company in 2023
Figure 29. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Geographic Region in 2023
Figure 31. Americas Intravitreal Injection of Anti-VEGF Drugs Sales 2019-2024 (K Units)
Figure 32. Americas Intravitreal Injection of Anti-VEGF Drugs Revenue 2019-2024 ($ millions)
Figure 33. APAC Intravitreal Injection of Anti-VEGF Drugs Sales 2019-2024 (K Units)
Figure 34. APAC Intravitreal Injection of Anti-VEGF Drugs Revenue 2019-2024 ($ millions)
Figure 35. Europe Intravitreal Injection of Anti-VEGF Drugs Sales 2019-2024 (K Units)
Figure 36. Europe Intravitreal Injection of Anti-VEGF Drugs Revenue 2019-2024 ($ millions)
Figure 37. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales 2019-2024 (K Units)
Figure 38. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Revenue 2019-2024 ($ millions)
Figure 39. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country in 2023
Figure 40. Americas Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Country (2019-2024)
Figure 41. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Figure 42. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Application (2019-2024)
Figure 43. United States Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 44. Canada Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 45. Mexico Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 46. Brazil Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 47. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Region in 2023
Figure 48. APAC Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Region (2019-2024)
Figure 49. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Figure 50. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Application (2019-2024)
Figure 51. China Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 52. Japan Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 53. South Korea Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast Asia Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 55. India Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 56. Australia Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 57. China Taiwan Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 58. Europe Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country in 2023
Figure 59. Europe Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Country (2019-2024)
Figure 60. Europe Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Figure 61. Europe Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Application (2019-2024)
Figure 62. Germany Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 63. France Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 64. UK Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 65. Italy Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 66. Russia Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country (2019-2024)
Figure 68. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Application (2019-2024)
Figure 70. Egypt Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 71. South Africa Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 72. Israel Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 73. Turkey Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC Countries Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Intravitreal Injection of Anti-VEGF Drugs in 2023
Figure 76. Manufacturing Process Analysis of Intravitreal Injection of Anti-VEGF Drugs
Figure 77. Industry Chain Structure of Intravitreal Injection of Anti-VEGF Drugs
Figure 78. Channels of Distribution
Figure 79. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Forecast by Region (2025-2030)
Figure 80. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Intravitreal Injection of Anti-VEGF Drugs
Figure 2. Intravitreal Injection of Anti-VEGF Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Intravitreal Injection of Anti-VEGF Drugs Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Intravitreal Injection of Anti-VEGF Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country/Region (2023)
Figure 10. Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Monoclonal Antibodies
Figure 12. Product Picture of Fusion Proteins
Figure 13. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type in 2023
Figure 14. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Type (2019-2024)
Figure 15. Intravitreal Injection of Anti-VEGF Drugs Consumed in Wet Age-Related Macular Degeneration
Figure 16. Global Intravitreal Injection of Anti-VEGF Drugs Market: Wet Age-Related Macular Degeneration (2019-2024) & (K Units)
Figure 17. Intravitreal Injection of Anti-VEGF Drugs Consumed in Diabetic Macular Edema
Figure 18. Global Intravitreal Injection of Anti-VEGF Drugs Market: Diabetic Macular Edema (2019-2024) & (K Units)
Figure 19. Intravitreal Injection of Anti-VEGF Drugs Consumed in Macular Edema Secondary to Retinal Vein Occlusion
Figure 20. Global Intravitreal Injection of Anti-VEGF Drugs Market: Macular Edema Secondary to Retinal Vein Occlusion (2019-2024) & (K Units)
Figure 21. Intravitreal Injection of Anti-VEGF Drugs Consumed in Others
Figure 22. Global Intravitreal Injection of Anti-VEGF Drugs Market: Others (2019-2024) & (K Units)
Figure 23. Global Intravitreal Injection of Anti-VEGF Drugs Sale Market Share by Application (2023)
Figure 24. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Application in 2023
Figure 25. Intravitreal Injection of Anti-VEGF Drugs Sales by Company in 2023 (K Units)
Figure 26. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Company in 2023
Figure 27. Intravitreal Injection of Anti-VEGF Drugs Revenue by Company in 2023 ($ millions)
Figure 28. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Company in 2023
Figure 29. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Geographic Region in 2023
Figure 31. Americas Intravitreal Injection of Anti-VEGF Drugs Sales 2019-2024 (K Units)
Figure 32. Americas Intravitreal Injection of Anti-VEGF Drugs Revenue 2019-2024 ($ millions)
Figure 33. APAC Intravitreal Injection of Anti-VEGF Drugs Sales 2019-2024 (K Units)
Figure 34. APAC Intravitreal Injection of Anti-VEGF Drugs Revenue 2019-2024 ($ millions)
Figure 35. Europe Intravitreal Injection of Anti-VEGF Drugs Sales 2019-2024 (K Units)
Figure 36. Europe Intravitreal Injection of Anti-VEGF Drugs Revenue 2019-2024 ($ millions)
Figure 37. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales 2019-2024 (K Units)
Figure 38. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Revenue 2019-2024 ($ millions)
Figure 39. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country in 2023
Figure 40. Americas Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Country (2019-2024)
Figure 41. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Figure 42. Americas Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Application (2019-2024)
Figure 43. United States Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 44. Canada Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 45. Mexico Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 46. Brazil Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 47. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Region in 2023
Figure 48. APAC Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Region (2019-2024)
Figure 49. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Figure 50. APAC Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Application (2019-2024)
Figure 51. China Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 52. Japan Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 53. South Korea Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast Asia Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 55. India Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 56. Australia Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 57. China Taiwan Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 58. Europe Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country in 2023
Figure 59. Europe Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share by Country (2019-2024)
Figure 60. Europe Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Figure 61. Europe Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Application (2019-2024)
Figure 62. Germany Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 63. France Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 64. UK Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 65. Italy Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 66. Russia Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Country (2019-2024)
Figure 68. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa Intravitreal Injection of Anti-VEGF Drugs Sales Market Share by Application (2019-2024)
Figure 70. Egypt Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 71. South Africa Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 72. Israel Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 73. Turkey Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC Countries Intravitreal Injection of Anti-VEGF Drugs Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Intravitreal Injection of Anti-VEGF Drugs in 2023
Figure 76. Manufacturing Process Analysis of Intravitreal Injection of Anti-VEGF Drugs
Figure 77. Industry Chain Structure of Intravitreal Injection of Anti-VEGF Drugs
Figure 78. Channels of Distribution
Figure 79. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Forecast by Region (2025-2030)
Figure 80. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global Intravitreal Injection of Anti-VEGF Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global Intravitreal Injection of Anti-VEGF Drugs Revenue Market Share Forecast by Application (2025-2030)
